First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

Morabito, Alessandro; Piccirillo, Maria Carmela; Monaco, Katia; Pacilio, Carmen; Nuzzo, Francesco; Chiodini, Paolo; Gallo, Ciro; Matteis, A. De; Perrone, Francesco

doi:10.1634/theoncologist.12-11-1288

Cited by 11 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of a high cardiac risk associated with increasing cumulative anthracycline dose, patients are often denied re-treatment in advanced setting; the choice of a liposomal anthracycline allows the possibility of re-treating an anthracycline-responsive disease without substantially increasing the cardiac risk [36]; this option should not be excluded in fact, and some evidences come from a recent report on first- line chemotherapy selection in adjuvant anthracycline-pretreated patients, where no differences have been found between CMF-based and anthracycline-containing regimens for their impact on the outcome of first-line anthracycline treatment [41]. By this point of view, even if our results are in anthracycline-naïve patients, the activity and the low toxicity profile observed suggest that the choice of a liposomal formulation can offer the chance of a more tolerable regimen maintaing conventional anthracyclines efficacy.…”

Section: Discussionmentioning

confidence: 99%

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Vici¹,

Colucci²,

Giotta³

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundTo evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naïve relapsed breast cancer patients.MethodsPatients with relapsed breast cancer not previously treated with adjuvant anthracyclines were randomly assigned to epirubicin/vinorelbine (arm A: EPI/VNB, EPI 90 mg/m2 on day 1, VNB 25 mg/m2 on days 1,5 plus G-CSF subcutaneously on days 7-12, with cycles repeated every 21 days), or to pegylated liposomal doxorubicin/VNB (arm B: PLD/VNB, PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, with cycles repeated every 4 weeks). Primary objective was to evaluate the efficacy of the two regimens in terms of response rate, secondarily toxicity, progression free survival and overall survival.ResultsOne hundred and four patients have been enrolled (arm A 54, arm B 50): characteristics were well balanced between the 2 arms. Responses were as follows: arm A, 3 (5.6%) CR, 20 (37%) PR, (ORR 42.6%, 95%CI 29.3%-55.9%); arm B, 8 (16%) CR, 18 (36%) PR, (ORR 52%, 95%CI 38.2%-65.8%). Median progression free survival was 10.7 months in arm A (95% CI, 8.7-12.6), and 8.8 months in arm B (95% CI, 7.1-10.5). Median overall survival was 34.6 months in arm A (95%CI, 19.5-49.8) and 24.8 months in arm B (95%CI, 15.7-33.9). As toxicity concerns, both treatment regimens were well tolerated; myelosuppression was the dose-limiting toxicity, with G3-4 neutropenia occurring in 18.5% and 22% of the patients of arm A and B, respectively. No relevant differences in main toxic effects have been observed between the two arms, except for alopecia, more common in arm A, and cutaneous toxicity, observed only in arm B. No clinical congestive heart failures have been observed, one case of tachyarrhythmia was reported after the last EPI/VNB cycle, and two reversible ≥ 20% LVEF decreases have been observed in arm A.ConclusionsBoth anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naïve relapsed breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Vici¹,

Colucci²,

Giotta³

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…The polychemotherapy arm patients showed an improved response rate, TTP and OS compared to the docetaxel arm patients. This study was the first to show an advantage of a combination regimen vs. monotherapy in MBC, and this regimen was established as the first-line combination in MBC refractory to anthracyclines [2,3,12]. Unfortunately, the combination therapy arm patients in this study suffered an increased haematological and non-haematological toxicity, especially due to gastrointestinal side effects and the hand-foot syndrome.…”

Section: Introductionmentioning

confidence: 95%

“…Some groups consider that it is not worthwhile to retreat these patients with anthracyclines, proposing instead docetaxel monotherapy or docetaxel with capecitabine as the most appropriate choice [3,12].…”

Section: Introductionmentioning

confidence: 99%

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…An estimated 1.6 million new cases of cancer and 0.6 million cancer-related deaths are predicted for the year 2017 (Cancer Facts & Figures, 2017, American Cancer Society). Cancers that spread to many parts of the body require more rigorous and comprehensive treatment regimens that usually involve chemotherapy as the first-line approach (Morabito et al, 2007; Telli & Carlson, 2009; Younes, Pereira, Fares, & Gross, 2011). Most chemotherapy drugs are difficult to administer directly, due to hydrophobicity.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery

Amreddy

Babu

Muralidharan

et al. 2018

Advances in Cancer Research

235

145

View full text Add to dashboard Cite

Effective and safe delivery of anticancer agents is among the major challenges in cancer therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability, and lack in vivo stability. Recent advancements in nanotechnology provide safe and efficient drug delivery systems for successful delivery of anticancer agents via nanoparticles. The physicochemical and functional properties of the nanoparticle vary for each of these anticancer agents, including chemotherapeutics, nucleic acid-based therapeutics, small molecule inhibitors, and photodynamic agents. The characteristics of the anticancer agents influence the design and development of nanoparticle carriers. This review focuses on strategies of nanoparticle-based drug delivery for various anticancer agents. Recent advancements in the field are also highlighted, with suitable examples from our own research efforts and from the literature.

show abstract

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

Cited by 11 publications

References 53 publications

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer

Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery

Contact Info

Product

Resources

About